Document is current

Article History

Received: 17 November 2024

Revised: 12 January 2025

Accepted: 19 February 2025

First Online: 1 March 2025

Competing interests

: MAK-D reports grant/research from Bristol Myers Squibb, Novartis and Pharmacyclics, and lecture/honorarium from Kite Pharma; NE (Epperla) reports research funding from Beigene and Eli Lilly. Speakers Bureau for Beigene, Incyte, and Novartis. Ad board for ADC Therapeutics. NA reports Ad Board participation for Bristol Myers Squibb. Consultancy fees for Kite/ Gilead. MH reports research support/Funding: ADC Therapeutics, Spectrum Pharmaceuticals, Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, AbbVie, Caribou, Genmab, Autolus. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, Bei Gene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. PRG reports consultancy services to Kite/Gilead Pharma, Bristol Myers Squibb (BMS) and served on the advisory boards of Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals. AB reports honoraria from Autolus and Kite Pharma. BD reports stocks in Syndax and Iovance Biotherapeutics. Honoraria: MJH Healthcare Holdings, LLC, Curio Science, Gilead Sciences. Consulting/Advisory: Janssen Oncology, Boxer Capital, ADC Therapeutics, Ellipsis, Acrotech Biopharma. Speakers’ Bureau: Gilead Sciences. Research: Pfizer, Poseida therapeutics, MEI Pharma, Angiocrine Bioscience, Takeda, Janssen Oncology, WUGEN, Inc., Orca Bio, Gilead Sciences, AlloVir, Molecular Templates, Atara Biotherapeutics. Travel/accomodations: Poseida. UG reports research/grant support from Bristol Myers Sqibb, Kite Pharma and Novartis. Consultancy/speaker bureau from Kite Pharma. JM reports consulting for Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly. Research funding from Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene. Honoraria from Targeted Oncology, OncView, Curio, and Physicians’ Education Resource. JS-S reports Speaking for Pfizer (SeaGen) and Ad Board for SeaGen, MassiveBio, ADC therapeutics, Genmab, BeiGene, AbbVie, and Bristol Myers Squibb. FLL reports consulting/advisory role for Allogene, Amgen, bluebird bio, Bristol Myers Squibb, Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja Biopharma, and Wugen; research funding from Allogene, Kite, and Novartis; and patents, royalties, other intellectual property from several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. FL reports advisory board for ADC Therapeutics. OOO reports consultancy and advisory board for Pfizer, Kite, Gilead, AbbVie, Janssen, TGR therapeutics, ADC, Novartis, Epizyme, Curio science, Nektar, Cargo, Caribou. Institution funding from Kite, Pfizer, Daichi Sankyo, Allogene. Honoraria from Pfizer, Gilead. MDJ reports consultancy/advisory for Kite/Gilead, Novartis. Research funding from Kite/Gilead, Incyte, and Loxo@Lilly. TS reports consultancy for BioLine Rx. MAM reports consultancy for AbbVie. JMc reports consulting for Envision, Novartis, Caribou Bio, Sana Technologies, Legend Biotech. Ad Board participation for Autolus, Consulting/Ad Board for Kite/Scimentum, AlloVIr, Bristol Myers Squibb, CRISPR, Nektar. YL reports consulting/advisory board for Janssen, Sanofi, Bristol Myers Squibb, Regeneron, Genentech. Research from Janssen, Bristol Myers Squibb. Scientific Advisory Boards for NexImmune, Caribou. DSMB/EDMC for Pfizer. SY reports consulting for Bristol Myers Squibb and Advisory board for Kite Pharma. JCC Reports advisory/consulting role for Genmab, ADC Therapeutics, Kite/Gilead, Novartis, Astrazeneca, Cellectis, Allogene, BMS, Janssen, Abbvie, Beigene, Pfizer. Research support from Genmab, Merck, Janssen, RM, NE (Easwar), PJ, MI, MN, JF, EA, KA, APR, OSA, LL, JL declare no relevant conflicts of interest to disclose.